Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Hypoparathyroidism Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Hypoparathyroidism Overview | 7 | 1 |
| Hypoparathyroidism Therapeutics under Development by Companies | 8 | 1 |
| Hypoparathyroidism Pipeline Products Glance | 9 | 3 |
| Late Stage Products | 9 | 1 |
| Clinical Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Hypoparathyroidism Products under Development by Companies | 12 | 1 |
| Hypoparathyroidism Companies Involved in Therapeutics Development | 13 | 4 |
| Ascendis Pharma A/S | 13 | 1 |
| Chugai Pharmaceutical Co Ltd | 14 | 1 |
| Eli Lilly and Company | 15 | 1 |
| Shire Plc | 16 | 1 |
| Hypoparathyroidism Therapeutics Assessment | 17 | 9 |
| Assessment by Monotherapy Products | 17 | 1 |
| Assessment by Target | 18 | 2 |
| Assessment by Mechanism of Action | 20 | 2 |
| Assessment by Route of Administration | 22 | 2 |
| Assessment by Molecule Type | 24 | 2 |
| Drug Profiles | 26 | 10 |
| Eu-232 Drug Profile | 26 | 1 |
| parathyroid hormone Drug Profile | 27 | 4 |
| PCO-371 Drug Profile | 31 | 1 |
| PTH-RM Drug Profile | 32 | 1 |
| Recombinant Peptide to Agonize Parathyroid Hormone Receptor for Hypoparathyroidism Drug Profile | 33 | 1 |
| Recombinant Protein to Agonize PTHR1 for Hypoparathyroidism Drug Profile | 34 | 1 |
| teriparatide Drug Profile | 35 | 1 |
| Hypoparathyroidism Dormant Projects | 36 | 1 |
| Hypoparathyroidism Product Development Milestones | 37 | 13 |
| Featured News &Press Releases | 37 | 1 |
| Jan 23, 2015: FDA approves Natpara to control low blood calcium levels in patients with hypoparathyroidism | 37 | 1 |
| Dec 02, 2014: European Medicines Agency Validates Marketing Authorization Application for Natpar (parathyroid hormone (rDNA)) in Hypoparathyroidism | 38 | 1 |
| Oct 23, 2014: PDUFA Action Date For Natpara BLA Extended Three Months To January 24, 2015 | 38 | 1 |
| Sep 12, 2014: FDA Advisory Committee Recommends Approval of Natpara for Long-Term Treatment of Hypoparathyroidism | 39 | 1 |
| Sep 12, 2014: FDA Advisory Committee to Review Natpara Biologics License Application | 39 | 1 |
| Sep 10, 2014: FDA Posts Briefing Materials for Advisory Committee Meeting Reviewing Natpara for Hypoparathyroidism | 39 | 1 |
| Jul 24, 2014: PARADOX Findings Published in Endocrine Practice Describe High Burden of Illness in Patients with Hypoparathyroidism | 40 | 1 |
| Jun 10, 2014: NPS Pharma Reports Change in Tentative Date of FDA Advisory Committee Review of Natpara BLA to September 12 - PDUFA Date of October 24 Remains Unchanged | 41 | 1 |
| Jan 07, 2014: NPS Pharmaceuticals Announces FDA Acceptance of Biologics License Application for Natpara for the Treatment of Hypoparathyroidism | 41 | 1 |
| Jan 03, 2014: NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara in Europe | 42 | 1 |
| Oct 24, 2013: NPS Pharmaceuticals Submits Biologic License Application to the U.S. Food and Drug Administration for Natpara in Hypoparathyroidism | 42 | 2 |
| Oct 07, 2013: Natpara Pivotal Study Published in The Lancet Diabetes &Endocrinology | 44 | 1 |
| Oct 07, 2013: New Findings from the REPLACE Study Suggest Natpara Has a Beneficial Effect on Bone Health in Patients with Hypoparathyroidism | 45 | 2 |
| Jun 17, 2013: NPS Pharma To Present Data On Natpara As Parathyroid Hormone Replacement Therapy In Patients With Hypoparathyroidism At ENDO 2013 | 47 | 2 |
| Jun 05, 2013: NPS Pharma Announces Presentation Of Data From Natpara REPLACE Study And PARADOX Study At ENDO 2013 | 49 | 1 |
| Appendix | 50 | 2 |
| Methodology | 50 | 1 |
| Coverage | 50 | 1 |
| Secondary Research | 50 | 1 |
| Primary Research | 50 | 1 |
| Expert Panel Validation | 50 | 1 |
| Contact Us | 50 | 1 |
| Disclaimer | 51 | 1 |
